Novartis’ Panobinostat Review Panel Could Scrutinize Survival Data
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Oncologic Drugs Advisory Committee is slated to meet on Nov. 6 to consider Novartis’ HDAC inhibitor panobinostat for relapsed multiple myeloma and may also look closely at dosing issues.